Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
    Meeting Abstract

    Morgenstern, D. A.; Mora, J.; Chan, G. C.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
    Meeting Abstract

    Barlesi, F.; Wolf, J.; Ahn, M. J.; Doebele, R. C.; Paz-Ares, L.; Rolfo, C.; Siena, S.; Seto, T.; Ohe, Y.; Ou, S. H. I.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Real-world insights into patients (pts) with advanced NSCLC and MET alterations
    Meeting Abstract

    Bittoni, M.; Yang, J. C. H.; Shih, J. Y.; Peled, N.; Smit, E.; Camidge, R.; Carbone, D.; Oksen, D.; Boutmy, E.; Johne, A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
    Meeting Abstract

    Gaspar, N.; Campbell-Hewson, Q.; Bielack, S. S.; Campbell, M.; Bautista, F.; Meazza, C.; Janeway, K.; Dela Cruz, F. S.; Whittle, S.; Morgenstern, D. A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Meeting Abstract

    Shitara, K.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P. C.; Ilson, D. H.; Kim, S.; Lordick, F.; Shah, M. A.; van Cutsem, E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
    Meeting Abstract

    Friedlander, M. L.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
    Meeting Abstract

    Hong, D. S.; Bang, Y. J.; Barlesi, F.; Durm, G.; Falchook, G. S.; Govindan, R.; Dy, G. K.; Park, K.; Strickler, J. H.; Burns, T. F.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
    Meeting Abstract

    Yang, J. C. H.; Le, X.; Cho, B. C.; Han, J. Y.; Morise, M.; Chen, Y. M.; Kang, J. H.; Kato, T.; Takeoka, H.; Chikamori, K.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
    Meeting Abstract

    Yoshino, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Vittrup Jensen, B.; Henrik Jensen, L; Smith, D.; Garcia-Carbonero, R.; Alcaide-Garcia, J.; Gibbs, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update
    Meeting Abstract

    Kang, Y. K.; Jones, R. L.; von Mehren, M.; Serrano, C.; George, S.; Heinrich, M. C.; Schoffski, P.; Mir, O.; Cassier, P. A.; Eskens, F.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save